J Chancellor - Concepedia

Author

J Chancellor

Health Economics and Outcomes Research (United Kingdom)

Also Known As

J CHANCELLOR, J Chancellor, J. Chancellor, Jeremy Chancellor, Jeremy V. Chancellor, Jeremy V.M. Chancellor

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Health Economics and Outcomes Research (United Kingdom)Pfizer (United States)Sanofi (France)University of York Pfizer (United Kingdom)

About

J Chancellor is an author at Health Economics and Outcomes Research (United Kingdom) specializing in medicine, public health, and health economics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	477
2	Public Health	8	8	386
3	Epidemiology	4	4	213
4	Diabetes	2	2	54
5	Health Sciences	1	1	27

J Chancellor

Publications

651

Citations

H-Index

Page 1

	Year	Citations
Research into the use of health economics in decision making in the United Kingdom—Phase II Tessa Duthie, Paul Trueman, J Chancellor, Health Policy United Kingdom—phase IiMedical Decision MakingHealth PolicyHealth EconomicsEconomic Evaluation	1999	89
Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection J Chancellor, Andrew Hill, Caroline Sabin, PharmacoEconomics Hiv/aids CounsellingHealth EconomicsTreatment And PreventionHiv InfectionLamivudine/zidovudine Combination Therapy	1997	76
The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model Samuel Aballéa, J Chancellor, Monique Martin, Value in Health VaccinationPeople Aged 50Preventive MedicineHealth EconomicsInternational Health	2007	72
Cost‐effectiveness analysis of oxaliplatin compared with 5‐fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US Samuel Aballéa, J Chancellor, Maria Raikou, Cancer	2007	68
Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland J Chancellor, Elke Hunsche, Edith de Cruz, PharmacoEconomics Specific InhibitorChemoprevention StrategyMedicinePharmacologyPharmacotherapy	2001	62
An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada Richard A. Zabinski, Thomas Burke, Fr d ric Lavoie, PharmacoEconomics RheumatologyHealth PolicyHealth EconomicsRheumatic DiseasesEconomic Model	2001	58
An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia* Michael Drummond, Debbie Becker, Margaret Hux, CHEST Journal AntibioticsHealthcare-associated InfectionIv/po Co-amoxiclavRespiratory InfectionAntimicrobial Pharmacokinetics	2003	53
Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens J Chancellor, Samuel Aballéa, Alison Lawrence, PharmacoEconomics Diabetes ManagementHealth PolicyInsulin ManagementDiabetesDiabetes Mellitus	2008	38
The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain Samuel Aballéa, J DEJUANES, Michelangela Barbieri, Vaccine VaccinationPreventive MedicineHealth EconomicsModel-based AnalysisInfluenza Vaccination	2007	33
Cost-Effectiveness of a Recommendation of Universal Mass Vaccination for Seasonal Influenza in the United States Karen M. Clements, J Chancellor, Kristin L. Nichol, Value in Health VaccinationPreventive MedicineUniversal Mass VaccinationHealth EconomicsHealth Policy	2011	32

Page 1